Heparan Sulfate Proteoglycans: Structure, Protein Interactions and Cell Signaling
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Emerging Views of Heparan Sulfate Glycosaminoglycan Structure
chain contains a b-D-glucosamine linked to an uronic acid, which can be one of two C5 epimers, either a-L-iduronic or b-D-glucuronic acid. Other than the C5 Emerging Views of Heparan Sulfate position of the uronic acid, HLGAGs Glycosaminoglycan Structure/Activity vary in their chain length, that is, the number of disaccharide repeat units, and Relationships Modulating Dynamic degree of sulfation and acetylation of each disaccharide unit. O-sulfation of the Biological Functions disaccharide repeat can occur at the 2-O Zachary Shriver, Dongfang Liu, and Ram Sasisekharan* position of the uronic acid and the 6-O and 3-O positions of the glucosamine. Thus, for a given disaccharide unit within an HSGAG structure, each site is Heparan sulfate glycosaminoglycans (HSGAGs) are an important subset either sulfated or unsubstituted, creat- of complex polysaccharides that represent the third major class of biopoly- ing eight possible combinations. In ad- mer, along with polynucleic acids and polypeptides. However, the impor- dition, as mentioned above, there are two possibilities for the uronic acid com- tance of HSGAGs in biological processes is underappreciated because of a ponent of each disaccharide unit, that lack of effective molecular tools to correlate specific structures with func- is, either iduronic acid or glucuronic tions. Only recently have significant strides been made in understanding acid, giving rise to a total of 16 different the steps of HSGAG biosynthesis that lead to the formation of unique possible disaccharide combinations. Fi- nally, the N-position of the glucosamine structures of functional importance. Such advances now create possibili- can be sulfated, acetylated, or unsubsti- ties for intervening in numerous clinical situations, creating much-needed tuted (three possible states). -
Early Acute Microvascular Kidney Transplant Rejection in The
CLINICAL RESEARCH www.jasn.org Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens Marianne Delville,1,2,3 Baptiste Lamarthée,4 Sylvain Pagie,5,6 Sarah B. See ,7 Marion Rabant,3,8 Carole Burger,3 Philippe Gatault ,9,10 Magali Giral,11 Olivier Thaunat,12,13,14 Nadia Arzouk,15 Alexandre Hertig,16,17 Marc Hazzan,18,19,20 Marie Matignon,21,22,23 Christophe Mariat,24,25 Sophie Caillard,26,27 Nassim Kamar,28,29 Johnny Sayegh,30,31 Pierre-François Westeel,32 Cyril Garrouste,33 Marc Ladrière,34 Vincent Vuiblet,35 Joseph Rivalan,36 Pierre Merville,37,38,39 Dominique Bertrand,40 Alain Le Moine,41,42 Jean Paul Duong Van Huyen,3,8 Anne Cesbron,43 Nicolas Cagnard,3,44 Olivier Alibeu,3,45 Simon C. Satchell,46 Christophe Legendre,3,4,47 Emmanuel Zorn,7 Jean-Luc Taupin,48,49,50 Béatrice Charreau,5,6 and Dany Anglicheau 3,4,47 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Although anti-HLA antibodies (Abs) cause most antibody-mediated rejections of renal allo- grafts, non-anti–HLA Abs have also been postulated to contribute. A better understanding of such Abs in rejection is needed. Methods We conducted a nationwide study to identify kidney transplant recipients without anti-HLA donor-specific Abs who experienced acute graft dysfunction within 3 months after transplantation and showed evidence of microvascular injury, called acute microvascular rejection (AMVR). -
Perlecan Antagonizes Collagen IV and ADAMTS9/GON-1 in Restricting the Growth of Presynaptic Boutons
The Journal of Neuroscience, July 30, 2014 • 34(31):10311–10324 • 10311 Development/Plasticity/Repair Perlecan Antagonizes Collagen IV and ADAMTS9/GON-1 in Restricting the Growth of Presynaptic Boutons Jianzhen Qin,1,2 Jingjing Liang,1 and X Mei Ding1 1State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China, and 2University of Chinese Academy of Sciences, Beijing 100049, China In the mature nervous system, a significant fraction of synapses are structurally stable over a long time scale. However, the mechanisms that restrict synaptic growth within a confined region are poorly understood. Here, we identified that in the C. elegans neuromuscular junction, collagens Type IV and XVIII, and the secreted metalloprotease ADAMTS/GON-1 are critical for growth restriction of presyn- apticboutons.Withoutthesecomponents,ectopicboutonsprogressivelyinvadeintothenonsynapticregion.Perlecan/UNC-52promotes the growth of ectopic boutons and functions antagonistically to collagen Type IV and GON-1 but not to collagen XVIII. The growth constraint of presynaptic boutons correlates with the integrity of the extracellular matrix basal lamina or basement membrane (BM), which surrounds chemical synapses. Fragmented BM appears in the region where ectopic boutons emerge. Further removal of UNC-52 improves the BM integrity and the tight association between BM and presynaptic boutons. Together, our results unravel the complex role of the BM in restricting the growth of presynaptic boutons and reveal the antagonistic function of perlecan on Type IV collagen and ADAMTS protein. Key words: ADAMTS9/GON-1; basement membrane; perlecan/UNC-52; presynaptic boutons; Type IV collagen/EMB-9; Type XVIII collagen/CLE-1 Introduction wider and present in the form of a basal lamina or basement Synapses are specialized intercellular junctions between neu- membrane (BM) (Palay and Chan-Palay, 1976; Burns and Au- rons or between neurons and other excitable cells. -
3D Distribution of Perlecan Within Intervertebral Disc Chondrons Suggests Novel Regulatory Roles for This Multifunctional Modular Heparan Sulphate Proteoglycan A.J
EuropeanAJ Hayes etCells al. and Materials Vol. 41 2021 (pages 73-89) DOI: 10.22203/eCM.v041a06 Nuclear and cytoplasmic localisation ISSN of1473-2262 perlecan 3D DISTRIBUTION OF PERLECAN WITHIN INTERVERTEBRAL DISC CHONDRONS SUGGESTS NOVEL REGULATORY ROLES FOR THIS MULTIFUNCTIONAL MODULAR HEPARAN SULPHATE PROTEOGLYCAN A.J. Hayes1 and J. Melrose2,3,4,* 1 Bioimaging Research Hub, Cardiff School of Biosciences, Cardiff University, Cardiff CF10 3AX, Wales, UK 2 Graduate School of Biomedical Engineering, UNSW Sydney, Sydney, NSW 2052, Australia 3 Raymond Purves Bone and Joint Research Laboratories, Kolling Institute of Medical Research, Royal North Shore Hospital and The Faculty of Medicine and Health, The University of Sydney, St. Leonards, NSW 2065, Australia 4 Sydney Medical School, Northern, Sydney University, Royal North Shore Hospital, St. Leonards, NSW 2065, Australia Abstract Perlecan is a modular, multifunctional heparan sulphate-proteoglycan (HS-PG) that is present in the pericellular and wider extracellular matrix of connective tissues. In the present study, confocal microscopy was used to study perlecan distribution within intervertebral disc chondrons. Perlecan immunolabel was demonstrated intracellularly and in close association with the cell nucleus within chondrons of both the annulus fibrosus (AF) and nucleus pulposus (NP). This observation is consistent with earlier studies that have localised HS-PGs with nuclear cytoskeletal components. Nuclear HS-PGs have been proposed to transport fibroblast growth factor (FGF)-1, FGF-2 and FGFR-1 into the cell nucleus, influencing cell proliferation and the cell-cycle. Perlecan has well-known interactive properties with FGF family members in the pericellular and extracellular matrix. Perinuclear perlecan may also participate in translocation events with FGFs. -
Demystifying Heparan Sulfate–Protein Interactions
UC San Diego UC San Diego Previously Published Works Title Demystifying heparan sulfate-protein interactions. Permalink https://escholarship.org/uc/item/0wj6876w Journal Annual review of biochemistry, 83(1) ISSN 0066-4154 Authors Xu, Ding Esko, Jeffrey D Publication Date 2014 DOI 10.1146/annurev-biochem-060713-035314 Peer reviewed eScholarship.org Powered by the California Digital Library University of California BI83CH06-Esko ARI 3 May 2014 10:35 Demystifying Heparan Sulfate–Protein Interactions Ding Xu and Jeffrey D. Esko Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California 92093; email: [email protected], [email protected] Annu. Rev. Biochem. 2014. 83:129–57 Keywords First published online as a Review in Advance on heparin-binding protein, glycosaminoglycan, proteoglycan, March 6, 2014 glycan–protein interaction, heparan sulfate–binding domain, The Annual Review of Biochemistry is online at oligomerization biochem.annualreviews.org Annu. Rev. Biochem. 2014.83:129-157. Downloaded from www.annualreviews.org This article’s doi: Abstract 10.1146/annurev-biochem-060713-035314 Access provided by University of California - San Diego on 06/23/20. For personal use only. Numerous proteins, including cytokines and chemokines, enzymes and Copyright c 2014 by Annual Reviews. enzyme inhibitors, extracellular matrix proteins, and membrane recep- All rights reserved tors, bind heparin. Although they are traditionally classified as heparin- binding proteins, under normal physiological conditions these proteins actually interact with the heparan sulfate chains of one or more mem- brane or extracellular proteoglycans. Thus, they are more appropriately classified as heparan sulfate–binding proteins (HSBPs). -
Cleavage of Lumican by Membrane-Type Matrix Metalloproteinase-1 Abrogates This Proteoglycan-Mediated Suppression of Tumor Cell Colony Formation in Soft Agar
[CANCER RESEARCH 64, 7058–7064, October 1, 2004] Cleavage of Lumican by Membrane-Type Matrix Metalloproteinase-1 Abrogates This Proteoglycan-Mediated Suppression of Tumor Cell Colony Formation in Soft Agar Yingyi Li,1 Takanori Aoki,1,3 Yuya Mori,1 Munirah Ahmad,1 Hisashi Miyamori,1 Takahisa Takino,1 and Hiroshi Sato1,2 1Department of Molecular Virology and Oncology and 2Center for the Development of Molecular Target Drugs, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan; and 3Daiichi Fine Chemical Co. Ltd., Takaoka, Toyama, Japan ABSTRACT or tumorigenicity in nude mice of rat fibroblast F204 cells trans- formed by K-ras or v-src oncogene (12). The small leucine-rich proteoglycan lumican was identified from a Matrix metalloproteinases (MMPs) are a family of Zn2ϩ-dependent human placenta cDNA library by the expression cloning method as a gene product that interacts with membrane-type matrix metalloproteinase-1 enzymes that are known to cleave extracellular matrix proteins in (MT1-MMP). Coexpression of MT1-MMP with lumican in HEK293T cells normal and pathological conditions (13). Currently, 23 MMP genes reduced the concentration of lumican secreted into culture medium, and have been identified in humans, and they can be subgrouped into this reduction was abolished by addition of the MMP inhibitor BB94. soluble-type and membrane-type MMPs (MT-MMPs; refs. 13, 14). Lumican protein from bovine cornea and recombinant lumican core MMPs are overexpressed in various human malignancies and have protein fused to glutathione S-transferase was shown to be cleaved at been thought to contribute to tumor invasion and metastasis by de- multiple sites by recombinant MT1-MMP. -
Glypican (Heparan Sulfate Proteoglycan) Is Palmitoylated, Deglycanated and Reglycanated During Recycling in Skin Fibroblasts
Glycobiology vol. 7 no. 1 pp. 103-112, 1997 Glypican (heparan sulfate proteoglycan) is palmitoylated, deglycanated and reglycanated during recycling in skin fibroblasts Gudrun Edgren1, Birgitta Havsmark, Mats Jonsson and granules (for reviews, see Kjell6n and Lindahl, 1991; Bernfield Lars-Ake Fransson et al., 1992; David, 1993; Heinegard and Oldberg, 1993). Pro- teoglycans are classified according to the characteristic fea- Department of Cell and Molecular Biology, Faculty of Medicine, Lund University, Lund, Sweden tures or properties of the core protein and can appear in many 'To whom correspondence should be addressed at: Department of Cell and glycoforms giving rise to considerable structural variation and Downloaded from https://academic.oup.com/glycob/article/7/1/103/725516 by guest on 30 September 2021 Molecular Biology 1, POB 94, S-221 00, Lund, Sweden functional diversity. In general, the protein part determines the destination of the proteoglycan and interacts with other mol- Skin fibroblasts treated with brefeldin A produce a recy- ecules at the final location. The glycan part provides the overall cling variant of glypican (a glycosylphosphatidylinositol- bulk properties as well as binding sites for other gly- anchored heparan-sulfate proteoglycan) that is resistant to cosaminoglycans and many types of proteins, including matrix inositol-specific phospholipase C and incorporates sulfate proteins, plasma proteins, enzymes, anti-proteinases, growth and glucosamine into heparan sulfate chains (Fransson, factors, and cytokines. L.-A. et aL, Glycobiology, 5, 407-415, 1995). We have now Cultured human fibroblasts synthesize, deposit, and secrete investigated structural modifications of recycling glypican, 3 a variety of proteoglycans and have been used extensively to such as fatty acylation from [ H]palmitate, and degrada- investigate both their biosynthesis and functional properties tion and assembly of heparan sulfate side chains. -
Curcumin Alters Gene Expression-Associated DNA Damage, Cell Cycle, Cell Survival and Cell Migration and Invasion in NCI-H460 Human Lung Cancer Cells in Vitro
ONCOLOGY REPORTS 34: 1853-1874, 2015 Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro I-TSANG CHIANG1,2, WEI-SHU WANG3, HSIN-CHUNG LIU4, SU-TSO YANG5, NOU-YING TANG6 and JING-GUNG CHUNG4,7 1Department of Radiation Oncology, National Yang‑Ming University Hospital, Yilan 260; 2Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung 40601; 3Department of Internal Medicine, National Yang‑Ming University Hospital, Yilan 260; 4Department of Biological Science and Technology, China Medical University, Taichung 404; 5Department of Radiology, China Medical University Hospital, Taichung 404; 6Graduate Institute of Chinese Medicine, China Medical University, Taichung 404; 7Department of Biotechnology, Asia University, Taichung 404, Taiwan, R.O.C. Received March 31, 2015; Accepted June 26, 2015 DOI: 10.3892/or.2015.4159 Abstract. Lung cancer is the most common cause of cancer CARD6, ID1 and ID2 genes, associated with cell survival and mortality and new cases are on the increase worldwide. the BRMS1L, associated with cell migration and invasion. However, the treatment of lung cancer remains unsatisfactory. Additionally, 59 downregulated genes exhibited a >4-fold Curcumin has been shown to induce cell death in many human change, including the DDIT3 gene, associated with DNA cancer cells, including human lung cancer cells. However, the damage; while 97 genes had a >3- to 4-fold change including the effects of curcumin on genetic mechanisms associated with DDIT4 gene, associated with DNA damage; the CCPG1 gene, these actions remain unclear. Curcumin (2 µM) was added associated with cell cycle and 321 genes with a >2- to 3-fold to NCI-H460 human lung cancer cells and the cells were including the GADD45A and CGREF1 genes, associated with incubated for 24 h. -
Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7, -
MALE Protein Name Accession Number Molecular Weight CP1 CP2 H1 H2 PDAC1 PDAC2 CP Mean H Mean PDAC Mean T-Test PDAC Vs. H T-Test
MALE t-test t-test Accession Molecular H PDAC PDAC vs. PDAC vs. Protein Name Number Weight CP1 CP2 H1 H2 PDAC1 PDAC2 CP Mean Mean Mean H CP PDAC/H PDAC/CP - 22 kDa protein IPI00219910 22 kDa 7 5 4 8 1 0 6 6 1 0.1126 0.0456 0.1 0.1 - Cold agglutinin FS-1 L-chain (Fragment) IPI00827773 12 kDa 32 39 34 26 53 57 36 30 55 0.0309 0.0388 1.8 1.5 - HRV Fab 027-VL (Fragment) IPI00827643 12 kDa 4 6 0 0 0 0 5 0 0 - 0.0574 - 0.0 - REV25-2 (Fragment) IPI00816794 15 kDa 8 12 5 7 8 9 10 6 8 0.2225 0.3844 1.3 0.8 A1BG Alpha-1B-glycoprotein precursor IPI00022895 54 kDa 115 109 106 112 111 100 112 109 105 0.6497 0.4138 1.0 0.9 A2M Alpha-2-macroglobulin precursor IPI00478003 163 kDa 62 63 86 72 14 18 63 79 16 0.0120 0.0019 0.2 0.3 ABCB1 Multidrug resistance protein 1 IPI00027481 141 kDa 41 46 23 26 52 64 43 25 58 0.0355 0.1660 2.4 1.3 ABHD14B Isoform 1 of Abhydrolase domain-containing proteinIPI00063827 14B 22 kDa 19 15 19 17 15 9 17 18 12 0.2502 0.3306 0.7 0.7 ABP1 Isoform 1 of Amiloride-sensitive amine oxidase [copper-containing]IPI00020982 precursor85 kDa 1 5 8 8 0 0 3 8 0 0.0001 0.2445 0.0 0.0 ACAN aggrecan isoform 2 precursor IPI00027377 250 kDa 38 30 17 28 34 24 34 22 29 0.4877 0.5109 1.3 0.8 ACE Isoform Somatic-1 of Angiotensin-converting enzyme, somaticIPI00437751 isoform precursor150 kDa 48 34 67 56 28 38 41 61 33 0.0600 0.4301 0.5 0.8 ACE2 Isoform 1 of Angiotensin-converting enzyme 2 precursorIPI00465187 92 kDa 11 16 20 30 4 5 13 25 5 0.0557 0.0847 0.2 0.4 ACO1 Cytoplasmic aconitate hydratase IPI00008485 98 kDa 2 2 0 0 0 0 2 0 0 - 0.0081 - 0.0 -
Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use
Molecules 2015, 20, 6342-6388; doi:10.3390/molecules20046342 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use Paola Chiodelli, Antonella Bugatti, Chiara Urbinati and Marco Rusnati * Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy; E-Mails: [email protected] (P.C.); [email protected] (A.B.); [email protected] (C.U.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-030-371-7315; Fax: +39-030-371-7747. Academic Editor: Els Van Damme Received: 26 February 2015 / Accepted: 1 April 2015 / Published: 10 April 2015 Abstract: Angiogenesis, the process of formation of new blood vessel from pre-existing ones, is involved in various intertwined pathological processes including virus infection, inflammation and oncogenesis, making it a promising target for the development of novel strategies for various interventions. To induce angiogenesis, angiogenic growth factors (AGFs) must interact with pro-angiogenic receptors to induce proliferation, protease production and migration of endothelial cells (ECs). The action of AGFs is counteracted by antiangiogenic modulators whose main mechanism of action is to bind (thus sequestering or masking) AGFs or their receptors. Many sugars, either free or associated to proteins, are involved in these interactions, thus exerting a tight regulation of the neovascularization process. Heparin and heparan sulfate proteoglycans undoubtedly play a pivotal role in this context since they bind to almost all the known AGFs, to several pro-angiogenic receptors and even to angiogenic inhibitors, originating an intricate network of interaction, the so called “angiogenesis glycomic interactome”. -
Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................